RIGL vs. FN
RIGL (Rigel Pharmaceuticals, Inc.) and FN (Fabrinet) are both stocks. RIGL operates in Biotechnology (Healthcare), while FN operates in Electronic Components (Technology). Over the past 10 years, RIGL returned 1.74%/yr vs 34.71%/yr for FN. At a 0.22 correlation, their price movements are largely independent.
Performance
RIGL vs. FN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RIGL achieves a -29.26% return, which is significantly lower than FN's 59.24% return. Over the past 10 years, RIGL has underperformed FN with an annualized return of 1.74%, while FN has yielded a comparatively higher 34.71% annualized return.
RIGL
- 1D
- 0.93%
- 1M
- 2.57%
- YTD
- -29.26%
- 6M
- -35.82%
- 1Y
- 48.60%
- 3Y*
- 29.35%
- 5Y*
- -5.31%
- 10Y*
- 1.74%
FN
- 1D
- 3.41%
- 1M
- 1.00%
- YTD
- 59.24%
- 6M
- 62.08%
- 1Y
- 202.25%
- 3Y*
- 84.79%
- 5Y*
- 50.58%
- 10Y*
- 34.71%
RIGL vs. FN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
RIGL Rigel Pharmaceuticals, Inc. | -29.26% | 154.64% | 16.00% | -3.33% | -43.40% | -24.29% | 63.55% | -6.96% | -40.72% | 63.03% |
FN Fabrinet | 59.24% | 107.06% | 15.53% | 48.44% | 8.23% | 52.69% | 19.66% | 26.37% | 78.78% | -28.78% |
Correlation
The correlation between RIGL and FN is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.16 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.23 |
Correlation (All Time) Calculated using the full available price history since Jun 28, 2010 | 0.22 |
The correlation between RIGL and FN shifts across timeframes, from 0.08 (1 year) to 0.23 (10 years), reflecting how their relationship changes across market environments.
Fundamentals
RIGL:
$596.49M
FN:
$26.26B
RIGL:
$19.21
FN:
$11.65
RIGL:
1.58
FN:
62.25
RIGL:
0.00
FN:
2.67
RIGL:
1.92
FN:
6.19
RIGL:
1.49
FN:
11.39
RIGL:
$299.77M
FN:
$4.24B
RIGL:
$279.95M
FN:
$509.75M
RIGL:
$125.80M
FN:
$422.55M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RIGL vs. FN — Risk / Return Rank
RIGL
FN
RIGL vs. FN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Rigel Pharmaceuticals, Inc. (RIGL) and Fabrinet (FN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| RIGL | FN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.42 | ||
| Sortino ratioReturn per unit of downside risk | -1.53 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.41 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | 0.98 | 9.90 | -8.93 |
| Martin ratioReturn relative to average drawdown | 1.74 | 24.13 | -22.39 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| RIGL | FN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.70 | 3.12 | -2.42 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.06 | 0.96 | -1.02 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.02 | 0.72 | -0.70 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.13 | 0.61 | -0.74 |
Drawdowns
RIGL vs. FN - Drawdown Comparison
The maximum RIGL drawdown since its inception was -99.37%, which is greater than FN's maximum drawdown of -70.46%. Use the drawdown chart below to compare losses from any high point for RIGL and FN.
Loading charts...
Drawdown Indicators
| RIGL | FN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.37% | -70.46% | -28.91% |
Max Drawdown (1Y)Largest decline over 1 year | -50.08% | -20.55% | -29.53% |
Max Drawdown (3Y)Largest decline over 3 years | -57.75% | -37.47% | -20.28% |
Max Drawdown (5Y)Largest decline over 5 years | -85.24% | -38.70% | -46.54% |
Max Drawdown (10Y)Largest decline over 10 years | -86.40% | -51.11% | -35.29% |
Current DrawdownCurrent decline from peak | -97.16% | -2.88% | -94.28% |
Average DrawdownAverage peak-to-trough decline | -90.91% | -22.59% | -68.32% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.99% | 8.42% | +19.57% |
Volatility
RIGL vs. FN - Volatility Comparison
The current volatility for Rigel Pharmaceuticals, Inc. (RIGL) is 19.96%, while Fabrinet (FN) has a volatility of 24.65%. This indicates that RIGL experiences smaller price fluctuations and is considered to be less risky than FN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RIGL | FN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.96% | 24.65% | -4.69% |
Volatility (6M)Calculated over the trailing 6-month period | 39.37% | 54.16% | -14.79% |
Volatility (1Y)Calculated over the trailing 1-year period | 69.85% | 65.29% | +4.56% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 85.52% | 53.25% | +32.27% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 82.82% | 48.08% | +34.74% |
Dividends
RIGL vs. FN - Dividend Comparison
Neither RIGL nor FN has paid dividends to shareholders.
Financials
RIGL vs. FN - Financials Comparison
This section allows you to compare key financial metrics between Rigel Pharmaceuticals, Inc. and Fabrinet. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
RIGL vs. FN - Profitability Comparison
RIGL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a gross profit of 54.21M and revenue of 58.82M. Therefore, the gross margin over that period was 92.2%.
FN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Fabrinet reported a gross profit of 144.34M and revenue of 1.21B. Therefore, the gross margin over that period was 11.9%.
RIGL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported an operating income of 11.89M and revenue of 58.82M, resulting in an operating margin of 20.2%.
FN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Fabrinet reported an operating income of 120.04M and revenue of 1.21B, resulting in an operating margin of 9.9%.
RIGL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a net income of 8.65M and revenue of 58.82M, resulting in a net margin of 14.7%.
FN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Fabrinet reported a net income of 128.18M and revenue of 1.21B, resulting in a net margin of 10.6%.
Frequently Asked Questions
RIGL and FN have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
FN has higher volatility (24.65%) compared to RIGL (19.96%). In terms of maximum drawdown, RIGL dropped -99.37% vs FN's -70.46%.
FN currently has the higher Sharpe Ratio (3.12 vs 0.70), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RIGL and FN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer